Skip to Content

Notice

Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is withdrawing approval of four new animal drug applications (NADAs) at the sponsor's request because the products are no longer manufactured or marketed.

DATES:

Withdrawal of approval is effective September 20, 2012.

FOR FURTHER INFORMATION CONTACT:

David Alterman, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-453-6843, email: david.alterman@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

The sponsors in table 1 of this document have requested that FDA withdraw approval of the four NADAs listed because the products are no longer manufactured or marketed.

Table 1—Withdrawal of Approval Requests

NADA No.Trade name (drug)Applicant
030-525NUMORPHAN (oxymorphone hydrochloride) InjectionEndo Pharmaceuticals Inc., 100 Painters Dr., Chadds Ford, PA 19317.
035-825NARCAN (naloxone hydrochloride) InjectionEndo Pharmaceuticals Inc., 100 Painters Dr., Chadds Ford, PA 19317.
046-822VETOCIN (oxytocin) InjectionUnited Vaccines, A Harlan Sprague Dawley, Inc., Co., P.O. Box 4220, Madison, WI 53711.
103-090CHORTROPIN (chorionic gonadotropin) InjectionUnited Vaccines, A Harlan Sprague Dawley, Inc., Co., P.O. Box 4220, Madison, WI 53711.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 030-525, 035-825, 046-822, and 103-090, and all supplements and amendments thereto, is hereby withdrawn, effective September 20, 2012.

Elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.

Dated: September 5, 2012.

Bernadette Dunham,

Director, Center for Veterinary Medicine.

[FR Doc. 2012-22195 Filed 9-7-12; 8:45 am]

BILLING CODE 4160-01-P